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Liposomes containing phosphatidylcholine have been widely used as adjuvants. 
Recently, we demonstrated that B-1 cells produce dipalmitoyl-phosphatidylcholine 
(DPPC)-specific IgM upon immunization of BALB/c mice with DPPC-liposomes encap-
sulating ovalbumin (OVA). Although this preparation enhanced the OVA-specific humoral 
response, the contribution of anti-DPPC antibodies to this effect was unclear. Here, 
we demonstrate that these antibodies are secreted by B-1 cells independently of the 
presence of OVA in the formulation. We also confirm that these antibodies are specific for 
phosphocholine. The anti-OVA humoral response was partially restored in B-1 cells-de-
ficient BALB/xid mice by immunization with the liposomes opsonized with the serum 
total immunoglobulin (Ig) fraction containing anti-phosphocholine antibodies, generated 
in wild-type animals. This result could be related to the increased phagocytosis by peri-
toneal macrophages of the particles opsonized with the serum total Ig or IgM fractions, 
both containing  anti-phosphocholine antibodies. In conclusion, in the present work, it 
has been demonstrated that phosphocholine-specific antibodies improve T-dependent 
antibody responses against OVA carried by DPPC-liposomes.
Keywords: B-1 cells, liposomes, phosphocholine-specific antibodies, peritoneal macrophages, humoral response
Abbreviations: APC, allophycocyanin; Chol, cholesterol; CW-PSC, cell wall polysaccharide; DMPC, dimyristoyl-phos-
phatidylcholine; DOPC, dioleoyl-phosphatidylcholine; DPPC, dipalmitoyl-phosphatidylcholine; DPPG, dipalmitoyl-phos-
phatidylglycerol; DRV, dehydration and rehydration vesicles; DSPC, distearoyl-phosphatidylcholine; ELISA, enzyme-linked 
immunosorbent assay; FITC, fluorescein isothiocyanate; i.p., intraperitoneal; Lp DPPC, DPPC and chol-containing liposomes; 
Lp DPPG, DPPG and chol-containing liposomes; Lp DPPC/OVA, DPPC and chol-containing liposomes encapsulating OVA; 
LPM, large peritoneal macrophages; OVA, ovalbumin; OVA-FITC, ovalbumin labeled with fluorescein isothiocyanate; PA, 
phosphatidic acid; PB, phosphate buffer; PerC, peritoneal cavity; PE Cy5.5, cyanine dye (Cy5.5) combined with phycoerythrin; 
PE, phycoerythrin; PEt, phosphatidylethanolamine; PS, phosphatidylserine; SM, sphingomyelin; SPM, small peritoneal mac-
rophages; SUV, small unilamellar vesicles; Xid, X-linked immunodeficient.
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inTrODUcTiOn
IgM is the first antibody isotype to appear during ontogeny and 
the only isotype produced by all species of vertebrates (1, 2). 
It is also the first isotype produced during an immune response 
and plays a crucial role in front-line host defense against 
pathogens. Secreted IgM plays important roles in the early 
phases of the adaptive immune response, as it concentrates 
antigen into secondary lymphoid organs, initiates antibody 
responses and germinal center formation, and accelerates 
affinity maturation in immune responses to thymus-dependent 
antigens (1, 3, 4).
Up to 80% of circulating IgM in the mouse derives from 
B-1 cells (5). B-1 cells represent the main B cell population of 
the peritoneal and pleural cavities in mice (6) and differ from 
conventional B lymphocytes (B-2) in surface markers, antibody 
repertoire, developmental pathway, and B-cell receptor (BCR) 
signaling (7). CD5 expression splits B-1 cells into two subsets: 
CD5+ B-1a and CD5− B-1b cells, which exhibit different functions 
in the immune system (8, 9). The natural repertoire of peritoneal 
B-1 cells contains phosphocholine and phosphatidylcholine-
specific antibodies, and hence they might interact with liposomes 
composed by this lipid (10–12). The so-called natural antibodies, 
mainly produced by these cells, are present in circulation without 
any evident antigenic challenge (13). The most studied natural 
antibodies bind to phosphorylcholine-containing antigens, 
which are present and accessible on apoptotic cell membranes 
and in oxidized low density lipoproteins, and also constitutes the 
immunodominant epitope in the pneumococcal cell wall poly-
saccharide (CW-PSC) (14–16). There is a distinct set of natural 
antibodies that bind to determinants that arise on erythrocytes 
during their senescence or after enzymatic treatment with bro-
melain (10, 17–19). These anti-red cell antibodies are reported 
to recognize determinants that involve the entire phosphati-
dylcholine molecule in the outer cell membrane, but not other 
phosphocholine-containing antigens.
Recently, we demonstrated the contribution of B-1 cells to 
the adjuvant properties of dipalmitoyl-phosphatidylcholine 
(DPPC) and cholesterol (Chol)-containing liposomes (Lp 
DPPC) encapsulating ovalbumin (OVA) (Lp DPPC/OVA) (20). 
BALB/X-linked immunodeficient (xid) mice, which exhibit 
defects in the B cell compartment, particularly in the B-1 cell 
population (21–23), showed quantitative and qualitative differ-
ences in the anti-OVA antibody response compared with wild-
type animals upon immunization with this preparation. The 
direct participation of B-1 cells was evidenced by the restoration 
of the immunostimulatory properties of Lp DPPC in BALB/xid 
mice adoptively transferred with B-1 cells purified from BALB/c 
animals; the internalization of these particles by B-1 cells; and 
the migration of B-1 cells from the peritoneal cavity (PerC) to 
the spleen. These cells were able to produce both in vitro and 
in  vivo DPPC-specific antibodies upon stimulation with Lp 
DPPC (20). These antibodies recognized sphingomyelin (SM) 
but not dipalmitoyl-phosphatidylglycerol (DPPG), suggesting 
their phosphocholine specificity. However, the precise contribu-
tion of these antibodies to the enhancement of the OVA-specific 
antibody response promoted by Lp DPPC encapsulating this 
antigen was not elucidated. In the present work, we character-
ized the anti-lipid antibody response induced by this liposomal 
preparation, its specificity, and the influence of the presence of 
the antigen. The presence of OVA in the formulation did not 
increase the anti-DPPC IgM response. These antibodies also rec-
ognized the CW-PSC from Streptococcus pneumoniae, corrobo-
rating their specificity for phosphocholine. The opsonization of 
Lp DPPC/OVA with these antibodies enhanced the anti-OVA 
humoral response in B-1 cells-deficient BALB/xid mice, although 
without reaching the levels obtained in wild-type animals. The 
particles opsonized with serum total immunoglobulin (Ig)- or 
IgM-containing phosphocholine-specific antibodies were effi-
ciently phagocyted by peritoneal macrophages, suggesting a role 
for these cells in the adjuvant properties of Lp DPPC.
MaTerials anD MeThODs
reagents
OVA grade V, used as model antigen in immunization protocols 
in soluble form or encapsulated into liposomes and OVA grade II, 
used to coat ELISA plates, were purchased from Sigma–Aldrich (St. 
Louis, MO, USA). CW-PSC from S. pneumoniae used to coat ELISA 
plates was purchased from Statens Seruminstitut (Copenhagen, 
Denmark). DPPC, DPPG, and Chol, used to generate liposomes 
and to coat ELISA plates, were purchased from Northern 
Lipids (Alabaster, AL, USA). Dimyristoyl-phosphatidylcholine 
(DMPC), distearoyl-phosphatidylcholine (DSPC), dioleoyl-
phosphatidylcholine (DOPC), SM, phosphatidic acid (PA), phos-
phatidylserine (PS), and phosphatidylethanolamine (PEt), used 
to coat ELISA plates, were purchased from Avantis Polar Lipids, 
Inc., Alabaster, AL, USA. Fluorescein isothiocyanate (FITC) from 
Sigma–Aldrich was used to label OVA. Dephosphorylated 18C 
polysaccharide from S. pneumoniae (dephos 18C PSC), used in 
the competitive ELISA, was generously provided by Dr. Janoi 
Chang from the Finlay Institute, Havana, Cuba.
Mice
Female BALB/c mice, 6 to 8 weeks of age, were purchased from 
the Center for Laboratory Animal Production (Havana, Cuba). 
Female and male BALB/xid mice, which carry a Bruton’s tyrosine 
kinase mutation and have a severely diminished B-1 cell popula-
tion (13, 23), were bred at the Center of Molecular Immunology 
(CIM; Havana, Cuba). All animals were specific pathogens-free 
and were maintained under standard animal house conditions 
with free access to water and standard rodent pellets.
ethics statement
All procedures were performed in compliance with the proto-
cols approved by the Institutional Committee for the Care and 
Use of Laboratory Animals of the CIM (CICUAL, 0017/2008). 
Animals were sacrificed by cervical dislocation, minimizing their 
suffering.
encapsulation of OVa into liposomes
Liposomes encapsulating OVA were obtained by a procedure 
based on dehydration and rehydration of vesicles (DRV) 
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developed by Kirby and Gregoriadis (24). To obtain OVA-
encapsulating liposomes, small unilamellar vesicles (SUV) 
composed of DPPC and an equimolar quantity of Chol were 
generated by ultrasonication and then mixed with OVA. After 
freezing at −70°C, the liposome and OVA mixture was lyophi-
lized in an Edwards freezer dryer (Aaron Equipment Company, 
Bensenville, IL, USA) for 24 h. The rehydration step was carried 
out with a small volume of distilled water (1 μL water/0.2 μmol of 
lipids) at 45°C, above the phase transition temperature of DPPC. 
After incubating for 30 min at 45°C, 0.5 mL of phosphate-buffered 
saline (PBS), pH 7.4, was added. Separation of non-encapsulated 
OVA was performed by centrifugation at 100,000 g for 30 min 
(Centrifuge 5415 R, Eppendorf AG, Hamburg, Germany). Empty 
liposomes comprised of DPPG and Chol (Lp DPPG), DPPC and 
Chol (Lp DPPC), or DPPG, PA, and Chol in a ratio 0.25:0.75:1 
(Lp DPPG:PA:Chol) (Lp DPPG:PA) were prepared following the 
same procedure, but in the absence of OVA.
Binding of antibodies induced by DPPc-
containing liposomes to cW-Psc
The recognition of CW-PSC by antibodies induced by Lp DPPC 
was tested by ELISA. 96-well polystyrene flat-bottom high bind-
ing microtiter plates (Maxisorp; Nunc, Roskilde, Denmark) were 
coated with 10 μg mL−1 of CW-PSC from S. pneumoniae diluted 
in PBS, pH 7.2, overnight at 4°C. The plates were blocked with 
5% (w/v) skim milk (Merck, Darmstadt, Germany) in PBS/0.05% 
Tween 20 (PBS/T) (v/v) (block solution I) for 1 h at 37°C. Serial 
dilutions of preimmune and immune serum samples were incu-
bated overnight at 4°C. Bound antibodies were detected with a 
biotinylated goat anti-mouse IgM antibody (AbD Serotec, Oxford, 
UK) followed by alkaline phosphatase-conjugated streptavidin 
(Sigma–Aldrich). A serum from a human donor immunized 
with the 7-valent pneumococcal polysaccharide–protein con-
jugate vaccine (PCV7; Prevnar®, Wyeth Lederle Vaccines) was 
used as positive control of CW-PSC recognition, and binding 
detected with a biotinylated goat anti-human IgM antibody 
(Jackson ImmunoResearch Laboratories Inc., West Grove, PA, 
USA) followed by alkaline phosphatase-conjugated streptavidin 
(Sigma–Aldrich). Chromogen p-nitrophenylphosphate diluted 
in diethanolamine/MgCl2 buffer, pH 5, was added as substrate 
solution and optical density read at 405  nm (OD405  nm) in a 
plate reader (ELISA Ledial01, Wiener Neudorf, Austria). Wells 
without coating and wells coated with CW-PSC and incubated 
only with the secondary antibodies were used as background 
controls.
For the competitive ELISA, plates coated with 10 μg mL−1 of 
CW-PSC from S. pneumoniae were incubated with immune sera 
from mice immunized with Lp DPPC previously mixed with 
different concentrations of Lp DPPC as competitor molecule. 
CW-PSC was used as positive control and Lp DPPG:PA and 
dephos 18C PSC as negative controls. Solutions of PSC at 50 and 
12 μg mL−1 and the liposomes at 80 and 20 μg mL−1 were mixed 
with the immune mouse sera diluted 1:100 in a ratio 1:1 (v/v) 
and incubated for 2 h at 37°C. Sera with or without competitor 
molecule were added to the plate and incubated overnight at 
4°C. After three washes, bound antibodies were detected with 
a biotinylated goat anti-mouse IgM antibody (AbD Serotec) 
followed by alkaline phosphatase-conjugated streptavidin 
(Sigma–Aldrich). The reaction was developed as describe above. 
The percentage of binding of immune sera in the presence of 
competitor molecule was determined with respect to signal in 
the absence of competitor molecule.
igM Purification from sera of Mice 
immunized with empty liposomes
To purify IgM fractions from sera of BALB/c mice immunized 
with empty Lp DPPC or Lp DPPG, Ig fractions were precipi-
tated with NH4SO4 and applied into a column of agarose with 
covalently attached goat anti-mouse IgM (μ-chain-specific) IgG 
fraction (Sigma–Aldrich). After washing the column with 0.01M 
sodium phosphate buffer, pH 7.2, containing 0.5M NaCl (PB), 
the elution step was carried out with 0.1M glycine with 0.15M 
NaCl, pH 2.4. Finally, the IgG contaminant was eliminated using 
a Hi-Trap protein G column (GE Healthcare Bio-Sciences AB, 
Uppsala, Sweden). The unbound fraction (IgM) was collected 
by washing the column with PB and the bound fraction (IgG) 
by eluting with 0.1M glycine–HCl buffer, pH 2.7. Both chroma-
tographic steps were performed at a flow rate of 1  mL min−1. 
Eluted fractions were neutralized using 200 μL of 1M Tris–HCl, 
pH 9.0. The protein concentration was estimated by absorbance 
at 280  nm. Polyacrylamide gel electrophoresis (SDS-PAGE) 
(25) and Western blotting analysis were performed to assess the 
purity of samples, using alkaline phosphatase-conjugated goat 
anti-mouse IgM (μ-chain-specific) and anti-mouse IgG (whole 
molecule) antibodies (Jackson ImmunoResearch), respectively. 
Molecular weight markers (Precision Plus Protein™ All Blue 
Standards) and IgM/IgG standards were purchased from Bio-
RAD (Waltham, MA, USA) and Sigma–Aldrich, respectively. In 
addition, IgM and IgG concentration was estimated by ELISA. 
The specificity of the IgM fraction for DPPC was also checked 
by ELISA.
igM and igg Quantification by elisa
To quantify the IgM fraction, 96-well polystyrene flat-bottom 
high binding microtiter plates (Corning™ Costar™, Thermo 
Fisher, Toronto, ON, Canada) were coated with a goat anti-mouse 
IgM (μ-chain-specific) antibody (Sigma–Aldrich), diluted 1:3500 
in 0.05M sodium carbonate buffer, pH 9.6 (coating buffer). The 
plates were incubated overnight at 4°C and blocked with 1% 
(w/v) of bovine serum albumin diluted in PBS (block solution 
II) for 30 min at 37°C. The samples diluted in block solution II 
were added and incubated for 2 h at 4°C. Serial dilutions (1:2) 
of an irrelevant mouse IgM (Sigma–Aldrich) were used as 
standard curve. Bound antibodies were detected with an alkaline 
phosphatase-conjugated goat anti-mouse IgM (μ chain-specific) 
antibody (Jackson ImmunoResearch), diluted 1:10,000 in block 
solution II after incubation for 1  h at 4°C. The reaction was 
developed as described above.
The IgG fraction was quantified using a similar assay, with a 
goat anti-mouse IgG (whole molecule) antibody (Sigma–Aldrich) 
diluted 1:333 as capture antibody, and samples diluted in PBS-
Tween 20 (0.05%) with fetal bovine serum (5%) (PBS-FBS). 
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Serial dilutions (1:2) of an irrelevant mouse IgG, produced at 
CIM (Havana, Cuba) were used as standard curve. After 1  h 
of incubation at 37°C, bound antibodies were detected using 
an alkaline phosphatase-conjugated goat anti-mouse IgG (Fcγ 
fragment-specific) (Jackson ImmunoResearch) diluted 1:10,000 
in PBS-FBS.
liposome Opsonization by 
Phosphocholine-specific antibodies
The opsonization assay was carried out by incubating Lp DPPC/
OVA with serum total Ig and IgM fractions for 2  h at 37°C. 
Bound antibodies were detected by flow cytometry using a 
PE-conjugated goat anti-mouse Ig antibody and PE-conjugated 
goat anti-mouse IgM, respectively (eBioscience, San Diego, CA, 
USA). To opsonize the amount of Lp DPPC/OVA correspond-
ing to one immunization dose, molar ratios antibodies:lipids of 
0.01:0.792 and 0.0001:0.792 were used for serum total Ig and IgM 
fractions, respectively.
immunization Protocols
The schedule followed in all intraperitoneal (i.p.) immunization 
protocols was one injection at day 0 and a booster after 14 days. 
Animals were bled at day 0 and 7 days after the booster. Anti-
OVA and anti-lipid antibody responses were evaluated by ELISA. 
BALB/xid mice were also immunized with OVA labeled with 
FITC (FITC-OVA) encapsulated into Lp DPPC (Lp DPPC/FITC-
OVA) opsonized or not with anti-phosphocholine antibodies-
containing serum total Ig fraction.
Determination of serum antibodies 
specific for OVa and lipids
To detect OVA-specific antibodies, 96-well polystyrene flat-
bottom high binding microtiter plates (Greiner-bio-one, 
Frickenhausen, Germany) were coated with 10 μg mL−1 of OVA 
diluted in coating buffer, overnight at 4°C. The plates were 
blocked with block solution I for 1 h at 37°C. Serial dilutions of 
serum samples were incubated for 2 h at 37°C. Bound antibod-
ies were detected with an alkaline phosphatase-conjugated goat 
anti-mouse IgG antibody (Sigma–Aldrich) or biotinylated goat 
anti-mouse IgG1 or IgG2a antibodies (AbD Serotec) followed 
by alkaline phosphatase-conjugated streptavidin (Sigma–
Aldrich). Serum dilutions giving signals corresponding to twice 
the value with the preimmune sera were considered as antibody 
titers.
To evaluate the presence of phosphocholine-specific antibod-
ies, 96-well polystyrene flat-bottom microtiter plates (Maxisorp; 
Nunc) were coated with 4 μg of DPPC, DSPC, DOPC, DMPC, 
DPPG, SM, PA, PS, or PEt diluted in n-hexane and incubated 
at 37°C until drying. The plates were blocked with 5% (w/v) 
skim milk (Merck) in PBS (blocking solution III) for 1 h at 37°C. 
Serum samples were diluted in blocking solution III, and plates 
were incubated overnight at 4°C. Bound antibodies were detected 
with a biotinylated goat anti-mouse IgM antibody (AbD Serotec) 
or a biotinylated goat anti-mouse IgG antibody (Sigma–Aldrich) 
followed by alkaline phosphatase-conjugated streptavidin 
(Sigma–Aldrich).
In both anti-OVA and anti-lipid determinations, the reaction 
was developed as described above.
evaluation of Opsonized lp DPPc/OVa 
Uptake by Peritoneal Macrophages In Vivo
BALB/xid mice (n =  3) were immunized i.p. with Lp DPPC/
FITC-OVA opsonized or not with anti-phosphocholine 
antibodies-containing serum total Ig fraction (Lp DPPC/
FITC-OVA  +  Ab and Lp DPPC/FITC-OVA, respectively). 
The IgM fraction from sera of BALB/c mice immunized with 
empty Lp DPPC (IgMDPPC) or Lp DPPG (IgMDPPG) and a com-
mercial irrelevant IgM (IgMirrelev) (Sigma–Aldrich) were also 
used to opsonize Lp DPPC/FITC-OVA. One hour later, cells 
were collected from the PerC by repeated washing with RPMI 
1640 medium (Sigma–Aldrich) and labeled with the follow-
ing goat anti-mouse antibodies combinations: PE-conjugated 
anti-F4/80 (PE-F4/80); cyanine dye (Cy5.5) combined with 
PE-conjugated anti-CD11b (PE Cy5.5-CD11b) and eFluor700-
conjugated anti-CD19 (eFluor700-CD19) or PE-conjugated 
anti-CD11b (PE-CD11b); PE cy-chrome 5 (Cy5)-conjugated 
anti-F4/80 (PE Cy5-F4/80), and allophycocyanin-conjugated 
anti-B220 (APC-B220). Macrophage populations were identi-
fied by flow cytometry from total cells as CD19−CD11b+ and 
F4/80+ (F4/80Low and F4/80High) (Figure S1 in Supplementary 
Material). Cells from non-immunized BALB/xid mice were used 
as negative control.
Flow cytometry analysis
For phenotype characterization, cell suspensions were pre-
incubated with an anti-CD16/CD32 mAb (BD Biosciences 
Pharmingen, San Diego, CA, USA) to block Fcγ II/III receptors 
before staining with fluorochrome-conjugated antibodies. Cells 
were stained with different combinations of goat anti-mouse anti-
bodies: PE-F4/80, PE-CD11b, PE-Cy5-F4/80, PE Cy5.5-CD11b, 
APC-B220, and eFluor700-CD19 using standard protocols. Cells 
were acquired using a Gallios flow cytometer (Beckman Coulter, 
Miami, FL, USA). The analysis was performed using the FlowJo 
7.2.2 software (Tree Star Ashland, OR, USA). Total number of 
macrophages was estimated by total cell number in the PerC 
counted in a Neubauer chamber.
statistical analysis
Statistical analysis was performed using the SPSS software 
version 16.0 (SPSS). The Kolmogorov–Smirnov test was used 
to verify normal distribution of data and the Levene test to 
determine the homogeneity of variance. Data with normal dis-
tribution and equality of variance were analyzed with one-way 
variance analysis (ANOVA) simple classification, with Tukey as 
post hoc test to assess statistical significance between the means 
of more than two groups. Data not normally distributed or 
without equality of variance, even after scale transformation, 
were analyzed using the Kruskal–Wallis non-parametric test 
with Dunn as post hoc test and the Friedman test with Dunn as 
post hoc test for matched data. For comparing the means of two 
independent groups, the Mann–Whitney U test or the Wilcoxon 
signed-rank test were used.
FigUre 1 | liposomal DPPc induces DPPc-specific igM in BalB/c, but not in BalB/xid mice. DPPC-specific IgM titers were evaluated by ELISA in (a) 
sera from BALB/c mice immunized i.p. with two doses of PBS (n = 20), Lp DPPC (n = 28), or Lp DPPC/OVA (n = 23); (B) sera from BALB/c mice (n = 17) 
immunized i.p. with one or two doses of Lp DPPC; (c) sera from BALB/c and BALB/xid mice immunized i.p. with two doses of PBS or Lp DPPC (n = 5 in each 
group). Means ± SEM are shown. Statistical analysis was performed with Kruskal–Wallis test with Dunn posttest (a,c) and Wilcoxon signed-rank test (B); *p < 0.05 
and ***p < 0.001.
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resUlTs
B-1 cells Produce anti-liposomal DPPc 
antibodies with specificity for 
Phosphocholine
To characterize the immune response induced by liposomal lipid 
DPPC, BALB/c mice were immunized with Lp DPPC with or 
without encapsulated OVA. As shown in Figure 1A, Lp DPPC, 
in the absence of antigen, induced similar DPPC-specific IgM 
response in BALB/c mice to those liposomes encapsulating OVA, 
used as control group. There were no differences in IgM titer after 
one or two administrations (Figure 1B), and no IgG antibodies 
were detected after immunization with empty liposomes (data 
not shown). Thus, liposomal DPPC induced a primary antibody 
response that was significantly impaired in B-1 cells-deficient 
BALB/xid mice (Figure 1C), indicating the crucial role of this B cell 
population, as had been demonstrated for Lp DPPC-containing 
OVA in our previously published experiments (20) and now 
confirmed with both empty and antigen-encapsulating particles.
The reactivity of sera from mice immunized with empty 
Lp DPPC against a panel of lipids, containing or not phos-
phocholine in their structure, was evaluated. As shown in 
Figure  2A, the signal ratio of immune sera over preimmune 
sera was only significantly higher than background in the 
cases of lipids containing the phosphocholine group (DSPC, 
DOPC, DPPC, DMPC, and SM). As expected, the immune sera 
did not recognize the lipids without phosphocholine (DPPG, 
PA, PS, and PEt). In addition, to evaluate the ability of these 
sera to recognize phosphocholine in a non-lipid molecule, we 
tested reactivity with CW-PSC from S. pneumoniae, a polysac-
charidic structure that only shares with DPPC the presence 
of the phosphocholine group (Figures  2B,C). As shown in 
Figure 2D, immune sera from mice showed similar reactivity 
against CW-PSC and DPPC. In contrast, a serum sample from 
FigUre 2 | antibodies induced by liposomal DPPc are specific for the phosphocholine group. (a) The recognition of a panel of lipids containing or not 
phosphocholine in their structure by sera from BALB/c mice immunized i.p with empty Lp DPPC (n = 11) was evaluated by ELISA. Sera were diluted 1:100, and the 
ratio of optical density at 405 nm between immune sera (OD405 nm iS) and preimmune sera (OD405 nm piS) was calculated. The following lipids were assessed: 
distearoyl-phosphatidylcholine (DSPC), dioleoyl-phosphatidylcholine (DOPC), dipalmitoyl-phosphatidylcholine (DPPC), dimyristoyl-phosphatidylcholine (DMPC), 
sphingomyelin (SM), dipalmitoyl-phosphatidylglycerol (DPPG), phosphatidic acid (PA), phosphatidylserine (PS), and phosphatidylethanolamine (PEt). The 2D 
structures of (B) the cell wall polysaccharide (CW-PSC) from S. pneumoniae and (c) DPPC were drawn using the Marvin Sketch program version 15.2.23.0 (2015), 
ChemAxon (http://www.chemaxon.com). (D) Serial dilutions of iS and piS from BALB/c mice immunized with Lp DPPC (n = 7) were evaluated by ELISA against 
DPPC and CW-PSC. A serum from a human donor immunized with a pneumococcal vaccine was used as positive control of CW-PSC recognition. Dashed and 
dotted lines indicate the background signal (without well coating) with mice and human serum, respectively. (e) The ability of Lp DPPC to inhibit the binding of 
DPPC-specific antibodies to CW-PSC was evaluated by a competitive ELISA. Sera from mice immunized with Lp DPPC were diluted 1:100, mixed 1:1 (v/v) with 
suspensions of Lp DPPC at two different concentrations (conc-1: 80 μg mL−1 and conc-2: 20 μg mL−1), and incubated for 2 h at 37°C. CW-PSC at conc-1: 50 μg 
mL−1 and conc-2: 12 μg mL−1 was used as positive control, while Lp DPPG:PA (a ratio 0.25:0.75) and dephos 18C PSC at the same concentrations that Lp DPPC 
and CW-PSC, respectively, were used as negative controls. The mixtures were added to an ELISA plate coated with CW-PSC and incubated overnight at 4°C. The 
percentage of binding to CW-PSC of sera in the presence of competitor molecule was calculated with respect to binding without competitor molecule. 
Means ± SEM are shown. Statistical analysis was performed with a Friedman test with Dunn posttest (a) and Kruskal–Wallis test with Dunn posttest (e); *p < 0.05, 
**p < 0.01, and ***p < 0.001.
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a human donor immunized with a pneumococcal vaccine only 
recognized CW-PSC (Figure 2D). To confirm that the structure 
recognized by mouse sera was the phosphocholine group in 
both molecules, we carried out a competitive ELISA against 
CW-PSC. The previous incubation of sera with Lp DPPC inhib-
ited binding to CW-PSC, in a concentration-dependent manner, 
similar to positive control CW-PSC. As expected, Lp DPPG:PA 
or dephos18C PSC did not affect the binding of sera to CW-PSC 
(Figure 2E) at any of the concentrations tested. Altogether, these 
results demonstrated the specificity for phosphocholine of the 
antibodies induced by empty Lp DPPC, which is in agreement 
with our previous data using OVA-encapsulating particles (20). 
FigUre 3 | Opsonization of lp DPPc/OVa with anti-phosphocholine antibodies-containing serum total ig fraction partially mimics in BalB/xid mice 
the OVa-specific antibody response induced by this liposomal formulation in wild-type animals. (a) Representative histograms of Lp DPPC/OVA 
opsonized with anti-phosphocholine antibodies-containing serum total Ig fraction (Lp DPPC/OVA + Ab) (black line), Lp DPPC/OVA alone (filled), and Lp DPPC/OVA 
opsonized with an isotype-matched control antibody (dotted line). OVA-specific (B) IgG, (c) IgG1, and (D) IgG2a were measured by ELISA in sera from BALB/xid 
mice (n = 5) immunized i.p. with two doses of Lp DPPC/OVA + Ab, and BALB/xid (n = 5) and BALB/c (n = 6) mice immunized i.p. with two doses of Lp DPPC/OVA. 
Means ± SEM are shown. Statistical analysis was performed with one-way ANOVA test with Tukey posttest (c) or Kruskal–Wallis test with Dunn posttest (B,D); 
*p < 0.05 and **p < 0.01.
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In the present work, this finding was reinforced by using a larger 
panel of phosphocholine-containing molecules.
Opsonization of lp DPPc/OVa with  
anti-Phosphocholine antibodies-containing 
serum Total ig Fraction Partially Mimics 
the B-1 cells-Mediated immunostimulatory 
effect of This Formulation
As in our previous report (20), we confirmed that the ability of Lp 
DPPC to potentiate the antibody response against encapsulated 
OVA was impaired in BALB/xid mice (Figure  3). To evaluate 
whether anti-phosphocholine antibodies participate in the B-1 
cells-mediated immunostimulatory effect of Lp DPPC, BALB/xid 
mice were immunized with Lp DPPC/OVA opsonized with the 
total Ig fraction from anti-DPPC antisera generated in wild-type 
animals (Lp DPPC/OVA + Ab). The Ig fraction ability to opsonize 
these particles was assessed by flow cytometry (Figure  3A). 
BALB/xid mice immunized with Lp DPPC/OVA + Ab exhibited 
significantly increased anti-OVA IgG titers in comparison with 
those induced by Lp DPPC/OVA alone, although without reach-
ing the levels obtained in wild-type animals (Figure 3B). Whereas 
almost no IgG1 response was observed in any of the BALB/xid 
mouse groups (Figure 3C), the levels of IgG2a reproduced the 
results of the total IgG titers (Figure  3D). In summary, the 
opsonization with anti-phosphocholine antibodies-containing 
total serum Ig fraction partially rescued the immunostimulatory 
properties of Lp DPPC in B-1 cells-deficient mice.
Opsonization with Phosphocholine-
specific antibodies increases the Uptake 
of lp DPPc/OVa by Peritoneal 
Macrophages
The more abundant large peritoneal macrophages (LPMs) express 
high levels of the canonical surface markers CD11b and F4/80 
(F4/80High macrophages), while small peritoneal macrophages 
(SPMs) express lower levels of these molecules (F4/80Low mac-
rophages) (26). We first assessed the uptake of Lp DPPC by both 
populations by immunizing BALB/xid mice with Lp DPPC/
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FigUre 4 | Opsonization of lp DPPc/OVa with anti-phosphocholine antibodies-containing serum total ig fraction improves the in vivo uptake of 
encapsulated OVa by peritoneal macrophages. BALB/xid mice (n = 3) were immunized i.p. with FITC-OVA encapsulated into Lp DPPC opsonized or not with 
anti-phosphocholine antibodies-containing serum total Ig fraction (Lp DPPC/FITC-OVA + Ab and Lp DPPC/FITC-OVA, respectively). Non-immunized BALB/xid mice 
were used as control. (a) Representative contour graphs of FITC-OVA vs. PE-F4/80 for both macrophage populations (F4/80Low and F4/80High) from one 
representative animal per group. Means ± SEM of the total number of antigen-loaded (B) F4/80Low and (c) F4/80High macrophages are shown. Statistical analysis 
was performed with Mann–Whitney U test: *p < 0.05.
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FITC-OVA previously opsonized or not with anti-phosphocho-
line antibodies-containing serum total Ig fraction. Peritoneal 
cells from each group were analyzed by flow cytometry following 
the gating strategy described in Figure S1 in Supplementary 
Material. BALB/xid mice immunized with opsonized Lp DPPC/
FITC-OVA showed a higher frequency of both phenotypes 
of peritoneal macrophages internalizing the labeled antigen 
(19.6% F4/80Low and 30% F4/80High) than in the case of animals 
receiving non-opsonized particles (5.2% F4/80Low and 17.7% 
F4/80High) (Figure 4A). In addition, a significant increase in the 
total number of antigen-loaded F4/80Low and F4/80High peritoneal 
macrophages was detected in animals receiving the opsonized 
liposomes in comparison with those that received non-opsonized 
vesicles (Figures 4B,C, respectively).
In order to determine if this effect was due to IgM-specific 
DPPC, we purified the IgM fraction from the anti-phosphocho-
line antibodies-containing serum total Ig preparation (IgMDPPC). 
Two affinity chromatography steps were necessary to obtain 
purified IgM. The eluted fraction from the IgM affinity chroma-
tography step still contained IgG contaminants, as shown in lines 
one of Figures  5A,C. When this fraction was applied into the 
protein G chromatographic column, a purified IgM preparation 
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FigUre 5 | analysis of purity and DPPc-reactivity of igM purified from anti-phosphocholine antibodies-containing sera. The IgM fraction purified 
from sera of BALB/c mice immunized with empty Lp DPPC was analyzed by SDS-PAGE and Western blot. (a) Silver-stained SDS-PAGE in 12% acrylamide under 
reducing conditions. The presence of (B) IgM and (c) IgG in each sample was determined by Western blot using alkaline phosphatase-conjugated goat 
anti-mouse IgM (μ-chain-specific) and anti-mouse IgG (whole molecule) antibodies, respectively. MW: molecular weight markers; IgM/IgG: standards. 1: eluted 
fraction from the IgM affinity chromatography applied into the protein G chromatography; 2: unbound fraction; and 3: eluted fraction. Recognition of DPPC by IgM 
from sera of animals immunized with Lp DPPC (IgMDPPC) or Lp DPPG (IgMDPPG), and by an irrelevant IgM (IgMirrelev) was assessed by (D) ELISA and (e) flow 
cytometry. In (e), representative histograms of Lp DPPC/OVA opsonized with IgMDPPC (black line), IgMDPPG (gray line), IgMirrelev (dotted line), and Lp DPPC/OVA 
alone (filled) are shown.
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was obtained, as determined by SDS-PAGE and Western blot 
(Figures 5A–C, lines 2). The absence of IgG in this preparation 
was also verified by ELISA (data not shown). The IgM fraction 
from sera of animals immunized with Lp DPPG was also puri-
fied using a similar strategy (IgMDPPG, data not shown). Only the 
IgM fraction from sera of animals immunized with Lp DPPC 
recognized DPPC, while IgMDPPG and IgMirrelev were not able to 
bind to it (Figure 5D). The opsonization of Lp DPPC/OVA with 
IgMDPPC, IgMDPPG, and IgMirrelev was assessed by flow cytometry 
(Figure 5E). As expected, the higher signal was obtained with the 
DPPC-specific IgM-enriched preparation.
Finally, the uptake of opsonized Lp DPPC/FITC-OVA by 
peritoneal macrophages was measured in BALB/xid mice. In 
agreement with the results showed in Figure 4, the frequency 
of both peritoneal macrophage populations (F4/80Low and 
F4/80High) loaded with the labeled antigen was higher with 
liposomes opsonized with IgMDPPC than with Lp DPPC/
FITC-OVA opsonized with IgMDPPG, IgMirrelev, or non-opsonized 
(Figure 6A). Moreover, the total numbers of macrophages from 
both populations (F4/80Low and F4/80High) internalizing the 
antigen were significantly higher in mice immunized with Lp 
DPPC/FITC-OVA opsonized with IgMDPPC than in the other 
FITC-OVA
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FigUre 6 | Opsonization of lp DPPc/OVa with anti-phosphocholine antibodies-containing serum igM fraction improves the in vivo uptake of 
encapsulated OVa by peritoneal macrophages. BALB/xid mice (n = 3) were immunized i.p. with FITC-OVA encapsulated into Lp DPPC (Lp DPPC/FITC-OVA) 
opsonized or not with the IgM fraction from sera of mice immunized with empty Lp DPPC (Lp DPPC/FITC-OVA + IgMDPPC) or Lp DPPG (Lp DPPC/FITC-
OVA + IgMDPPG). Non-immunized BALB/xid mice and a group of mice immunized with Lp DPPC/OVA opsonized with an irrelevant IgM (Lp DPPC/FITC-
OVA + IgMirrelev) were included as controls. (a) Representative contour graphs of FITC-OVA vs. PECy5-F4/80 for both macrophage populations (F4/80Low and 
F4/80High) from one representative animal per group. Means ± SEM of the total number of antigen-loaded (B) F4/80Low and (c) F4/80High macrophages are shown. 
Statistical analysis was performed with one-way ANOVA test with Tukey posttest (B) or Kruskal–Wallis test with Dunn posttest (c); *p < 0.05; **p < 0.01, and 
***p < 0.001.
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groups (Figures  6B,C, respectively). Neither IgMDPPG nor 
IgMirrelev improved the uptake of liposomes by macrophages.
DiscUssiOn
Secreted IgM is an important mediator in the optimal initiation 
of primary thymus-dependent humoral immune responses. It 
serves as a natural adjuvant by enhancing the immunogenicity 
of protein antigens, perhaps as a result of its ability to facilitate 
antigen deposition onto follicular dendritic cells and to promote 
rapid germinal center formation (1, 4, 27–29). Besides, the com-
plex antigen–IgM is involved in affinity maturation (3, 28). It has 
also been reported that secreted IgM influences BCR signaling 
and promotes survival of splenic B cells (30).
We have previously shown that B-1 cells contribute to the 
ability of DPPC-containing liposomes to enhance the encap-
sulated antigen-specific antibody response. Besides, liposomal 
DPPC stimulates B-1 cells to produce IgM, specific for the 
phosphocholine polar head (20). We therefore addressed here 
whether these antibodies contributed to the immunostimulatory 
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properties of Lp DPPC. The results described in the present work 
demonstrate that these particles were able to induce similar 
levels of DPPC-specific antibodies irrespective of the presence 
of encapsulated OVA. This response depended on B-1 cells, since 
it was significantly reduced in B-1 cells-deficient BALB/xid mice, 
as we previously reported for liposomes encapsulating OVA 
(20). Xid mice have extensively been used as a model of B-1 cell 
deficiency (13), and although these animals exhibit defects also 
in the B-2 cell compartment, higher doses of soluble OVA than 
the one we used in our work (2 μg) induced similar IgG titers in 
BALB/c and BALB/xid mice (our unpublished data), suggesting 
that the B-2 cell response against this antigen is not affected in 
the latter animals. Moreover, no significant differences have been 
found in the marginal zone B cell population between these two 
mouse strains (31).
The recognition of different lipid species containing phos-
phocholine in their structure, as well as the CW-PSC from 
S.  pneumoniae by the antibodies induced by liposomal DPPC 
corroborated their specificity for the phosphocholine group. On 
the other hand, the lack of reactivity with DPPC of the serum 
from a human donor immunized with a pneumococcal vaccine 
is in agreement with previous results in which rabbits immunized 
with this antigen conjugated to bovine serum albumin elicited 
antibodies that recognized the saccharide moiety but not the 
phosphocholine group (32).
The opsonization of Lp DPPC/OVA with phosphocholine-
specific antibodies partially mimicked the immunostimulatory 
effect of DPPC-liposomes in the OVA-specific humoral response, 
as proven in B-1 cells-deficient mice. Our results extend previous 
observations demonstrating a role for B-1 cells-derived IgM in 
the enhancement of IgG production by B-2 cells (28, 33).
IgM antibodies can promote humoral immune responses 
through complement activation (34) and engagement of recep-
tors, such as mannan-binding lectin (35), the polymeric Ig 
receptor (36), the Fc alpha/mu receptor (Fcα/μR) (37, 38), or 
the Fc receptor specific for IgM (FcμR) (38–41). The potential 
roles of different cellular receptors for IgM are a topic of active 
investigation. The Fcα/μR is constitutively expressed on mac-
rophages, in addition of other cells, such as B cells and follicular 
dendritic cells, and recognizes IgM and IgA with high and inter-
mediate affinity, respectively (37, 42). It mediates endocytosis 
of IgM-coated microbes (37, 43). On the other hand, the FcμR 
is expressed on macrophages and dendritic cells, although to 
a lesser extent in comparison with other immune cells like T 
and B lymphocytes (29, 39–42, 44). It plays an essential role in 
humoral immune responses to both thymus-dependent and 
-independent antigens (38, 44) and acts as an endocytic recep-
tor, internalizing antigen–IgM complex (45). The engagement 
of this pathway could result in synergistic activation of B cells 
stimulated through the BCR (46).
Liposomes coated with the anti-phosphocholine IgM 
produced by B-1 cells could be taken up more efficiently by 
antigen-presenting cells through IgM-specific receptors, thus 
enhancing the presentation of encapsulated antigens. Particularly 
in this work, we demonstrated that administration of liposomes 
opsonized with anti-phosphocholine antibodies-containing 
serum total Ig or IgM fractions enhanced the uptake of the 
antigen by both the large and the small populations of perito-
neal macrophages of BALB/xid mice, whose phagocytic activity 
in vivo has been demonstrated (26). This result is in agreement 
with other works showing that the incubation with polyclonal 
IgM enhances the phagocytosis of apoptotic cells in the lungs by 
alveolar macrophages (47) and promotes the clearance of apop-
totic microparticles released from dying cells (48). The increase 
in the opsonized Lp DPPC/OVA uptake by macrophages in vivo 
could be related to the improvement of the OVA-specific anti-
body response observed in BALB/xid mice immunized with 
this preparation. Interestingly, this humoral response was not 
completely restored in comparison with wild-type animals. 
Notably, B-1 cells-deficient animals were persistently unable 
to produce specific IgG1, despite the restoration of the IgG2a 
levels. This could be due to the role of these cells as IL-10 pro-
ducers, which inhibits IgG2a and favors IgG1 production (49). 
This observation suggests the direct participation of B-1 cells in 
the adjuvanticity of liposomes beyond the production of anti-
DPPC IgM. In agreement with this, we previously described the 
ability of B-1 cells to uptake and transport the antigen from the 
PerC to the spleen after intraperitoneal immunization with Lp 
DPPC/OVA (20).
In conclusion, in the present work, it has been demonstrated 
for the first time that B-1 cells-derived phosphocholine-specific 
antibodies induced by liposomal DPPC contribute to the immu-
nostimulatory properties of these particles.
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